findmyKOL
Clinical trialNCT00004918CompletedPhase 1/PHASE2Interventional

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

SponsorNational Cancer Institute (NCI)Enrollment69Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChronic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in Transformation+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 1999
Primary completion
31 Dec 2007
Completion
Last update posted
7 Jan 2013
Registered enrollment
69
Registry id
NCT00004918

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.